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Abstract
Previous reports have suggested that the ablation of the Period 2 gene (Per 2) leads to enhanced
development of lymphoma and leukemia in mice. Employing immunoblot analyses, we have
demonstrated that PER 2 is endogenously expressed in human breast epithelial cell lines but is not
expressed or is expressed at significantly reduced level in human breast cancer cell lines. Expression
of PER 2 in MCF-7 breast cancer cells significantly inhibited the growth of MCF-7 human breast
cancer cells, and, when PER 2 was co-expressed with the Crytochrome 2 (Cry 2) gene, an even
greater growth-inhibitory effect was observed. The inhibitory effect of PER 2 on breast cancer cells
was also demonstrated by its suppression of the anchorage-independent growth of MCF-7 cells as
evidenced by the reduced number and size of colonies. A corresponding blockade of MCF-7 cells
in the G1 phase of the cell cycle was also observed in response to the expression of PER 2 alone
or in combination with CRY 2. Expression of PER 2 also induced apoptosis of MCF-7 breast cancer
cells as demonstrated by an increase in PARP [poly (ADP-ribose) polymerase] cleavage. Finally, our
studies demonstrate that PER 2 expression in MCF-7 breast cancer cells is associated with a
significant decrease in the expression of cyclin D1 and an up-regulation of p53 levels.
Background
In mammals, most body functions follow a rhythmic pat-
tern adjusted to a 24 h period (circadian rhythm), which
is controlled by the circadian timing system [1,2]. Circa-
dian rhythmicity is an evolutionarily conserved property
that regulates numerous functions in the human body
including sleep and wakefulness, body temperature,
blood pressure, hormone production, digestive secretion,
and immune activity [3]. The circadian timing system
comprises peripheral oscillators located in most tissues of
the body and a central rhythm generator located in the
suprachiasmatic nucleus (SCN) of the hypothalamus [4].
The SCN pacemaker consists of multiple, autonomous
single cell circadian oscillators, which are synchronized to
fire rhythmically, generating a coordinated, rhythmic out-
put in intact animals [5,6].
The cellular mechanism of circadian rhythmicity involves
the regulation of three Period genes (Per 1–3) and two
Chrytochrome  genes (Cry1  and  2) [4]. Currently, it is
thought that transcription of Per and Cry genes is driven
by accumulating CLOCK:BMAL1 heterodimers, which in
turn bind to consensus E-box elements [7-10]. Subse-
quently, complexes of PER 2 and CRY 2 proteins enter the
Published: 11 March 2008
Journal of Circadian Rhythms 2008, 6:4 doi:10.1186/1740-3391-6-4
Received: 14 December 2007
Accepted: 11 March 2008
This article is available from: http://www.jcircadianrhythms.com/content/6/1/4
© 2008 Xiang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Circadian Rhythms 2008, 6:4 http://www.jcircadianrhythms.com/content/6/1/4
Page 2 of 9
(page number not for citation purposes)
nucleus, where they shut off CLOCK-mediated transcrip-
tion. At the same time, PER 2 up-regulates the levels of
BMAL1 mRNA leading to the formation of
CLOCK:BMAL1 heterodimers, which drive Per 2 and Cry
2 transcription and restart the cycle [11,12]. MOP4 (mem-
ber of the PAS superfamily 4), also named NPAS2, shares
high homology with CLOCK [13] and like CLOCK forms
a heterodimer with BMAL1, promoting E-box activation
of genes such as Per1 and vasopressin and is negatively
regulated by CRY 1 and 2 [11]. In adult animals, oscilla-
tory expression of CLOCK genes has been demonstrated
in the SCN and in several peripheral tissues. Interacting
positive and negative transcriptional-translational feed-
back loops drive circadian oscillators in both Drosphila
and mammals. Furthermore, immortalized rat fibroblasts
harbor a clock that can measure time with astonishing
precision [14]. The SCN clock is thought to synchronize
such peripheral clocks via both neural and hormonal sig-
nals.
For several years now, it has been known that disruption
of circadian rhythm increases the rate of tumorigenesis
[15,16], but until recently no molecular evidence was
available to explain this phenomenon. Breast cancer is
especially susceptible to circadian alterations due to the
fact that it is an endocrine responsive neoplasm, and
many hormones known to influence the development
and growth of the breast and breast cancer exhibit diurnal
rhythms of synthesis and secretion [17-21].
Numerous epidemiological studies have implied a role for
the circadian clock in breast cancer development. A Dan-
ish study investigating 30- to 54-year old women reported
that women who work predominantly night shifts, and
thus are exposed to light at night, show a significantly
increased risk of breast cancer [18]. The breast cancer risk
increases significantly with the number of years and hours
that individuals spend working at night [18,22]. Similar
results are described by Schernhammer et al. [23] who
examined 78,562 nurses that often alternate between day
and night shifts. A meta analysis of all of these studies
demonstrate that circadian rhythm interruption signifi-
cantly increases an individual's risk for the development
of breast cancer. Based on our work [24,25] and that of
others that melatonin, a photoperiodic hormone whose
expression is repressed by light, inhibits the growth and
development of breast cancer, we believe that pro-tumor-
igenic effects of light are mediated through melatonin and
its effect on the clock an circadian rhythms.
In tumor-bearing animals and cancer patients, circadian
disruption not only increases the risk of tumor develop-
ment, but also accelerates cancer progression and is asso-
ciated with poor prognosis and outcome. Filipski et al.
[26] demonstrated that complete ablation of the SCN in
mice results in loss of circadian rhythm as well as a two-
to three-fold increase in malignant growth when com-
pared to controls, leading to significant reductions in sur-
vival time. As well, carcinoma- or sarcoma-bearing rats
show an increase in tumor growth and a reduction in sur-
vival time when subjected to alternating photoperiods
[27]. Other studies that have disrupted circadian rhythms
in mice by targeted mutations of the core clock genes
engendering the molecular clock not only in the suprach-
iasmatic nuclei but in all peripheral organs have shown
effects on disruption of cell growth and spontaneous and
ionizing radiation-induced tumor incidence [28].
At present, the mechanism by which the circadian clock
affects tumor growth is not fully understood. Recently, the
circadian clock gene Per 2, which helps to synchronize
mammalian organisms with environmental photic cues,
has been reported to function as a tumor suppressor gene.
Fu et al. [28] observed the development of spontaneous
lymphomas and teratomas in Per 2 knockout mice at only
six months of age. Thirty per cent of the mutant mice died
before the age of 16 months. Disruption of the Per 2 gene
in mice abolishes the response of all core circadian genes
to gamma radiation whereas in wild-type mice the clock
genes are induced rapidly, suggesting they may be
involved in DNA damage response. Furthermore, a
number of cell cycle and checkpoint proteins were dereg-
ulated in these Per 2 mutant mice including cyclin D1,
cyclin A, mdm-2, gadd45α, and c-myc. The studies cited
above demonstrate the importance of circadian clock
genes, in particular Per 2, as regulators of the cell cycle
and, therefore, cancer progression. Based on the role of
PER 2 in cancer development and the clear epidemiologic
connection between circadian disruption (light at night)
and the risk of breast cancer development in women, we
hypothesize that the clock gene, Per 2, is expressed in nor-
mal human mammary epithelium and at a reduced level
in breast cancer cells leading to an alteration in the cell
cycle, cell growth, and cell survival.
Materials and methods
Human breast cancer and breast epithelial cell lines
The human breast cancer cell line MDA-MB-231 and the
immortalized MCF-10A human breast epithelial cell line
were purchased from American Tissue Type Culture Col-
lection (Rockville, MD). The MCF-7 breast tumor cell line
was obtained from the laboratory of the late William L.
McGuire (San Antonio, TX),. The T47D breast tumor cell
line was kindly provided by Dr. I. Keydar (Tel Aviv Univer-
sity, Israel). The human mammary epithelial cell line
hTERT-HME1 was provided by Dr. Matthew Burow
(Tulane University). All cells except hTERT-HME1 cells
were routinely maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum (FBS) [Gibco BRL,
Grand Island, NY], 2 mM glutamine, 50 mM MEM non-Journal of Circadian Rhythms 2008, 6:4 http://www.jcircadianrhythms.com/content/6/1/4
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essential amino acids, 1 mM sodium pyruvate, 10 mM
basal medium eagle (BME), 100 U/ml penicillin, and 100
mg/ml streptomycin. The hTERT-HME1 cells were grown
in serum-free MEBM medium (Cambrex Bio Science
Walkersville Inc., Walkersville, MD) supplemented with
52 μg/ml bovine pituitary extract. All cells were incubated
in a humidified atmosphere of 5% CO2 and 95% air at a
constant temperature of 37ºC.
Antibodies, plasmids and recombinant DNAs
The mouse antibody against human PER 2 and the rabbit
anti-goat IgG and horseradish peroxidase-conjugated sec-
ondary antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Mouse antibodies to PARP
[poly (ADP-ribose) polymerase], P53, Cyclin D1 and β-
actin were purchased from Sigma Chemical Co. (St. Louis,
MO). Recombinant DNAs for the human Per 2 and Cry 2
genes were kindly provided by David Virshup (Salt Lake
City, UT) and Charles Weitz (Harvard Medical School,
Boston, MA), respectively. Plasmids used in these studies
consisted of the pcDNA 3.1 vector and the GFP vector
pTracer™-CMV2, which were purchased from Invitrogen
(Carlsbad, CA).
Cell culture and transfection
MCF-7 breast cancer cells were maintained in RPMI 1640
supplemented with antibiotics (BioWhitaker, Walkers-
ville, MD, USA) and 10% FBS in a humidified atmosphere
of 5% CO2 at 37ºC. MCF-7 breast cancer cells were then
plated in 6-well plates at a density of 0.5 × 105 cells/well
(for protein isolation) or 2 × 104 cells/well (for growth
studies) in the same media and transfected on the follow-
ing day. The cells were transiently transfected with the
pcDNA 3.1 or pCS2+MT empty vectors or the same plas-
mids containing the human Per 2 or Cry 2 genes (400 ng/
well of plasmid or plasmid plus cDNA) using the FuGENE
6 transfection reagent (Roche Diagnostics, Indianapolis,
IN) for 6–8 h in serum-free medium. Following transfec-
tion the cells were re-fed with medium supplemented
with 10% FBS.
Protein isolation and Western blot analysis
MCF-7 cells were transiently transfected with empty vec-
tors,  Per 2 cDNA or both Per 2 and  Cry 2 cDNA as
described above. Forty eight hours post transfection, total
cellular protein was extracted by suspending the cell pel-
lets in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
0.1% SDS, 0.5% sodium deoxycholate, 0.1% Triton X-
100, 1 mM PMSF, 0.02% sodium azide, 1 mg/ml apro-
tinin and 1 mg/ml leupeptin) for 30 min at 4ºC and then
centrifuging at 10,000 × g for 10 min. Supernatants were
collected as total cellular protein and assayed for protein
concentration using the Bio-Rad protein assay system
(BioRad, Hercules, CA).
One hundred micrograms of total cellular protein per
sample was electrophoretically separated on a 10%
sodium dodecyl sulfate (SDS) polyacrylamide gel and
transferred onto a nylon membrane (Amersham Life Sci-
ence) by electroblotting. The membranes were blocked by
incubation for 90 min at room temperature with 5% (w/
v) nonfat dry milk in TBST (150 mM NaCl, 10 mM Tris-
HCl, 0.1% TWEEN), then incubated with antibodies
directed against the PER 2, PARP, p53, cyclin D1 or β-actin
(1:250 dilution) overnight at 4ºC, washed with TBST, and
incubated for 1 h at room temperature with horseradish
peroxidase-conjugated rabbit-anti-mouse IgG or goat-
anti-rabbit IgG (1:10,000 dilution; Amersham Life Sci-
ence) secondary antibody. Immunoreactive proteins were
visualized using the enhanced chemiluminescence system
(ECL; Amersham Life Science). Membranes were exposed
for 3 to 30 min to Kodak X-OMAT AR film. Expression val-
ues of proteins were normalized to the β-actin (loading
control) and quantitated by scanning densitometry using
a Bio-Rad GS-700 imaging densitometer.
Growth studies
MCF-7 breast cancer cells were plated in 6-well plates at a
density of 2 × 104 cells/well in media supplemented with
10% FBS and transfected on the following day. The cells
were transiently transfected with the pcDNA 3.1 vector or/
and the pCS2+MT empty vectors or the same plasmids
containing the human Per 2 or Cry 2 genes as described
above. On each day following transfection cells were har-
vested in phosphate-buffered saline (PBS)/EDTA solution
containing 0.1% trypsin and counted on a heamocytom-
eter every day for four days using the Trypan blue dye
exclusion method.
Soft agar clonogenic assay
MCF-7 cell were transfected with pTracer™-CMV2 or
pTracer™-CMV2-hPer 2 for 18 h, pTracer™-CMV2-positive
or pTracer™-CMV2-hPer 2-positive cells were sorted with
Becton Dickenson Flow Activated Cell Sorter (FACS) Aria.
Two thousand five hundred cells per well were seeded in
12-well plates (3.8 cm2) in culture medium containing
0.35% low-melting agarose over a 0.7% agarose base layer
and incubated for 12 days at 37ºC in a humidified 5%
CO2 atmosphere in RPMI 1640 media supplemented with
10% FBS. Colonies larger than 100 μm in diameter were
counted under a dissecting microscope. Each cell sample
was seeded in triplicate and soft agar assays were repeated
three separate times.
Cell cycle studies
MCF-7 cells were transiently transfected with empty vec-
tors, Per 2 cDNA or both Per 2 and Cry 2 cDNA. After three
days of expression, cells were harvested with PBS/EDTA
and the cells pelleted at 1000 × g for 5 minutes. Cell pel-
lets were washed once in cold PBS and resuspended inJournal of Circadian Rhythms 2008, 6:4 http://www.jcircadianrhythms.com/content/6/1/4
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500 μl of cold PBS with 0.1% glucose. Five milliliters of
cold 70% ethanol, were added to the cell suspension and
the cells were kept at 4ºC for 30 min. to 12 h. Cells were
pelleted at 1000 × g for 5 minutes, the supernatant
removed and the cells washed with 5 ml of cold PBS. The
cells were then resuspended in 300 μl of propidium
iodide (PI)/Triton X-100 staining solution with RNase A,
and incubated for 30 min at 37ºC. Samples were then
examined for cell cycle phase by flow cytometry
(BDLSR11; Becton Dickinson, San Jose, CA).
Results
Expression of PER 2 in human breast epithelial and breast 
cancer cell lines
Total cellular protein was isolated from two immortalized
human breast epithelial cell lines (HME-tert and MCF-
10A), two ERα-positive human breast tumor cell lines
(MCF-7 and T47D lines) and one ERα-negative human
breast tumor cell lines (MDA-MB-231), and was exam-
ined by Western blot analysis using an antibody directed
against the human PER 2 protein (Figure 1). Expression of
PER 2 was evident in the two breast epithelial cell lines,
but was not observed in MCF-7 and T47D cell lines. It was
present in the MDA-MB-231 cell line, but at a level greatly
reduced compare to the breast epithelial cell lines.
Effect of PER 2 and CRY 2 on the growth of MCF-7 cells
Cell proliferation assays were conducted on parental, vec-
tor-transfected, Per 2 transfected and expressing MCF-7
cells, Cry 2 transfected and expressing MCF-7 cells, and
MCF-7 cells transfected with and expressing both Per 2
and Cry 2. Following transfection, cell number and cell
viability were assessed by hemacytometer cell counts and
trypan blue staining (Figure 2). A significant 31.6%
decrease in cell number was seen in cells expressing PER 2
on day 4, but not in cells expressing CRY 2. However,
when both PER 2 and CRY 2 were expressed in the same
cells a significant 44.6% and 61.81% suppression of cell
proliferation was noted as compared to control cells on
day 2 and day 4 respectively.
PER 2 expression reduces MCF-7 cell growth in soft agar
To assess the effect of PER 2 on in vitro tumorigenicity, soft
agar clonogenic assays were performed with MCF-7 cells
(Figure 3). After 12 days in culture, control cells trans-
fected with the pTracer™-CMV2 displayed a clonogenic
efficiency of 27% (25.00 ± 1.86 colonies), whereas MCF-
7 cells transfected with and expressing PER 2 demon-
strated a significantly reduced efficiency to 1.6% (4.11 ±
0.86 colonies). The difference in clonogenic efficiency
between these two cell groups was determined to be
highly significant (P < 0.001). In addition to clonogenic
efficiency, the size of colonies formed by pTracer™-CMV2
vector transfected cells (376 ± 37 μm) was significantly
Effect of PER 2 and CRY 2 on the growth of MCF-7 cells Figure 2
Effect of PER 2 and CRY 2 on the growth of MCF-7 
cells. Cell proliferation assays were conducted on parental, 
vector-transfected, PER 2 overexpressing MCF-7 cells, CRY 2 
overexpressing MCF-7 cells, and cells over expressing both 
PER 2 and CRY 2. Cells were counted on a hemacytometer 
using the trypan blue stain every day for four days. N = 3 
independent experiments in triplicate. *a = p < 0.05 vs. 
pCS2+pCDNA3.1, *b = p < 0.05 vs. Per2, *c = p < 0.05 vs. 
pCS2
Expression of PER 2 in human breast epithelial and breast  cancer cell lines Figure 1
Expression of PER 2 in human breast epithelial and 
breast cancer cell lines. Total cellular protein was isolated 
from two immortalized human breast epithelial cell lines 
(HME-tert and MCF-10A), two ERα-positive human breast 
tumor cell lines (MCF-7 and T47D lines) and one ERα-nega-
tive human breast tumor cell lines (MDA-MB-231 line). One 
hundred micrograms of total cellular protein from each cell 
line was separated by 10% polyacrylamide gel electrophoresis 
and subjected to Western blot analysis using an antibody 
directed against the human PER 2 protein.Journal of Circadian Rhythms 2008, 6:4 http://www.jcircadianrhythms.com/content/6/1/4
Page 5 of 9
(page number not for citation purposes)
larger (p < 0.05) than those formed by Per 2 transfected
cells (163 ± 18 μm).
Effect of PER 2 and CRY 2 on the cell cycle of MCF-7 cells
To determine if the decrease in cell proliferation induced
by the expression of PER 2 or PER 2 and CRY 2 is a result
of alteration in the cell cycle, we conducted cell cycle anal-
yses on parental, vector-transfected, Per 2 transfected and
expressing MCF-7 cells, Cry 2 transfected and expressing
MCF-7 cells, and cells transfected with and expressing
both Per 2 and Cry 2 (Table 1). The expression of PER 2 in
MCF-7 cells resulted in a significant increases (25.8%) in
the percentage of cells in the G1 phase of the cell cycle as
compared to vector transfected controls and a significant
decrease (60%) in the percentage of cells in S phase, vs.
vector transfected controls. The combined expression of
both PER 2 and CRY 2 resulted in an even greater increase
(42.5%) in the percentage of cells in G1 by demonstrating
a blockade of MCF-7 breast cancer cells blocked at the G1/
S border.
PER 2 expression induces apoptosis in MCF-7 breast 
cancer cells
To determine if the decreased growth in MCF-7 cells trans-
fected with Per 2 or Per 2 and Cry 2 was the result of
increased apoptosis we conduced PARP-cleavage assays.
Seventy two hours post transfection cells were harvested
and total cell extracts prepared and subjected to Western
blot analysis using an antibody directed against the 85
kDa cleaved fragment of PARP [poly (ADP-ribose)
polymerase] (Figure 4). MCF-7 cells transfected and
expressing Per 2 displayed a significant increase (p <
0.001) in cleaved PARP protein levels by 714.2% when
compared to control vector transfected cells. These results
PER 2 expression induces apoptosis in MCF-7 breast cancer  cells Figure 4
PER 2 expression induces apoptosis in MCF-7 breast 
cancer cells. (A) MCF-7 cells were transiently transfected 
with empty vector, vector expressing PER 2, or both vectors 
expressing PER 2 or CRY 2. After 72 hours, total cell extracts 
were prepared and subjected to Western blot analysis using 
an antibody directed against the 85 kDa cleaved fragment of 
PARP [poly (ADP-ribose) polymerase] (representative of 
three independent studies). (B) Densitometric analysis of 
cleaved PARP protein (average value of three independent 
studies). a. PER 2 or PER 2 + CRY 2 vs vector control, p < 
0.001, b PER 2 + CRY 2 vs PER 2, p < 0.01
PER 2 expression reduces MCF-7 cell growth in soft agar Figure 3
PER 2 expression reduces MCF-7 cell growth in soft 
agar. Soft agar clonogenic assays were performed with 
MCF-7 cells. MCF-7 cell were transfected with pTracer™-
CMV2 or pTracer™-CMV2-hPer 2 and sorted. Two thou-
sand five hundred cells per well were seeded in 12-well 
plates (3.8 cm2) in culture medium containing 0.35% low-
melting agarose over a 0.7% agarose base layer and incubated 
for 12 days. Colonies larger than 100 μm in diameter were 
counted.
Table 1: Effect of PER 2 and CRY 2 on the cell cycle of MCF-7 
cells
G1 S G2/M
GFP 7414 15.57 10.29
pCS2 65.36 18.03 16.61
PER2 82.24 7.16 10.60
pCS2 + pcDNA3.1 62.61 17.49 19.90
PER2 + CRY2 89.19 0.58 10.22
Cell cycle analyses were conducted on parental, vector-transfected, 
PER 2 overexpressing MCF-7 cells, CRY 2 overexpressing MCF-7 cells, 
and cells over expressing both PER 2 and CRY 2. After three days of 
expression, propidium iodide(PI) staining and samples were analyzed 
by flow cytometry.Journal of Circadian Rhythms 2008, 6:4 http://www.jcircadianrhythms.com/content/6/1/4
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show that expression of PER 2 induces apoptosis in MCF-
7 human breast cancer cells and that concomitant expres-
sion of PER 2 and CRY 2 further increase apoptosis in
MCF-7 human breast cancer cells by 689.5% (p < 0.001)
compared to transfection controls and 74% (p < 0.01)
compared to cells expressing PER 2 alone.
Effect of PER 2 on the expression of P53 and Cyclin D1
Given that expression of PER 2 and PER 2 plus CRY 2 in
MCF-7 cells results in decreased cell proliferation, alters
the cell cycle, and induces apoptosis, we asked if there
were associated changes in the expression of the cyclin D1
cell cycle associated gene and the DNA repair/apoptosis
associated p53 protein. Seventy two hours following
transfection with an empty vector (pcDNA 3.1) or the Per
2 expression construct, total cellular protein was extracted,
prepared and subjected to Western blot analysis using
antibodies directed against human p53 and cyclin D1
(Figure 5). Compared to vector transfected control cells,
PER 2 expressing cells displayed significantly elevated lev-
els (157% of controls) of p53 protein but significantly
decreased levels (56% reduced vs. controls) of cyclin D1
protein.
Discussion
Substantial epidemiological and clinical data demon-
strate that circadian rhythms greatly affect the diagnosis
and outcome of breast cancer patients. However, the
chronotherapeutic observations leading to the current
standard of treatment are serendipitous and lack a strong
cellular and molecular rationale. In the present study, we
provide further evidence indicating a role of circadian
rhythms and regulation of the cellular clock in the control
of the cell cycle and in human breast cancer cell growth
and proliferation. A common molecular circuitry is seen
in both central and peripheral oscillators [3,4]. The clock-
work machinery comprises a battery of transcriptional
activators and repressors that form an auto-regulatory
transcriptional feedback loop. Clock and BMAL1 are
paired transcriptional activators that drive the expression
of PER 1, 2, 3 and CRY 1, 2 and the nuclear orphan recep-
tor gene Rev-erbα. The PER/CRY protein complex inhibits
the transcription of its own genes by the Clock/BMAL1
transcriptional complex, while Rev-erbα binds to ROREs
in the BMAL1 promoter to block BMAL1 expression
[1,2,29,30]. This cell-autonomous feedback loop permits
PER 2 expression increases P53 but decreases cyclin D1 expression in MCF-7 cells Figure 5
PER 2 expression increases P53 but decreases cyclin D1 expression in MCF-7 cells. (A) MCF-7 cells were tran-
siently transfected with and empty vector (pcDNA 3.1) [U] or vector expressing PER 2 [T]. After 48 hours, total cell extracts 
were prepared and subjected to Western blot analysis using an antibodies directed against the P53 and PER 2 proteins. (B) 
Densitometric analysis of P53 protein expression. * p < 0.05. (C) Western blot analysis using an antibodies directed against the 
cyclin D1(cD1) and PER 2 proteins. (D) Densitometric analysis of cD1 protein expression. * p < 0.05.Journal of Circadian Rhythms 2008, 6:4 http://www.jcircadianrhythms.com/content/6/1/4
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cyclic expression of oscillator genes at various phases with
the same periodicity of approximately 24 h [2,31].
As a core clock gene, Per 2 functions to maintain the circa-
dian rhythm of the SCN and peripheral cells and also to
sustain the normal cell cycle. In our studies, contrary to
the report of Gery et al. [32], we found that PER 2 was
expressed in normal breast epithelial cell lines (HMCE-
Tert and MCF-10A) and in the ERα-negative MDA-MB-
231 breast tumor cell line, but not in MCF-7 and T47D
breast cancer cell lines. Several possibilities exist for this
discrepancy including the possibility that, in light of the
report that acute treatment of MCF-7 cells with estrogen
can modulate PER 2 expression, long term exposure to E2
in our culture media may down regulates PER 2 expres-
sion. It is also possible, that our MCF-7 line demonstrates
a different gene expression pattern than those used by
Gery et al. [32].
Our studies do, however, confirm that, when PER 2 is
expressed at elevated level in MCF-7 breast cancer cells, it
induces a significant growth-inhibitory effect. When PER
2 and CRY 2 are co-expressed an even greater enhance-
ment of growth-inhibition was seen as compared to cells
expressing only PER 2. Interestingly, the expression of
CRY 2 alone had no significant effect on MCF-7 cell pro-
liferation, suggesting CRY 2 is itself not a critical regulator
of cell cycle but that it functions to regulate cell cycle and
cell death in breast cancer cells by partnering with PER 2.
This inhibition of cell proliferation by PER 2 and PER 2/
CRY2 may be related to several events, including altera-
tion of the cell cycle and induction of apoptosis. As shown
in our studies, expression of PER 2 alone, or PER 2/CRY 2
blocked MCF-7 cell cycle at the G1/S border. The anti-pro-
liferative effects of PER 2 appear to be attributable to the
induction of apoptosis rather than just an elongation or
blockade of the cell cycle, as PER 2 expression in MCF-7
cells induces morphological changes, such as rounding up
and detachment that are consistent with programmed cell
death. The induction of apoptosis by PER 2 was con-
firmed by a significant increase in PARP [poly(ADP-
ribose)polymerase] cleavage, an indicator of activated cas-
pases [33].
Recent studies have reported that clock-controlled genes
are involved in the regulation of the cell cycle and apop-
tosis, including c-Myc, the tumor suppressor p53, and cyc-
lins [28]. Progression through G1 depends initially on
cyclin D-CDK4/6 protein complexes, and later on cyclin
E-CDK2. Cyclin D1 is a key cell cycle regulatory protein,
known to be up-regulated by estrogen, an established
breast cancer mitogen [34]. The down-regulation of cyclin
D1 plays an important role in the cell cycle arrest. Our
results indicate that expression of PER 2 significantly
down-regulates cyclin D1 level in MCF-7 cells, which may
contribute to the arrest in G1 of the cell cycle. Loss of p53
in many cancers leads to impaired cell cycle regulation,
genomic instability and inhibition of apoptosis. The
tumor suppressor p53 can induce a transient arrest in G1
in cells, allowing cells time to repair damaged DNA [35].
Activated p53 can also eliminate cells through mecha-
nisms involving prolonged arrest in G1 and induction of
apoptosis. The elimination of abnormally proliferating
cells by p53 is considered to be the principal means by
which p53 mediates tumor suppression [35,36]. The
expression of PER 2 in MCF-7 cells significantly increase
p53 levels. Our data confirms in human breast cancer cells
the results obtained by Hua et al [36] in Per 2 mutant
mice. The elevated expression of P53 in PER 2 expressing
breast cancer cells may contribute, at least in part, to both
arrest in G1 of the cell cycle and apoptosis. PER 2 may
induce tumor cell apoptosis by the p53-mediated mito-
chondrial signaling pathway. The mechanism by which
PER 2 regulates Cyclin D1 and p53 expression is under
investigation in our laboratory.
Anchorage-independent growth in soft agar as a character-
istic of in vitro tumorigenicity is correlated with enhanced
tumor progression and metastasis and is a hallmark of
malignant transformation and, thus, is an effective
method to evaluate the growth and tumorigenicity of cells
in vitro [37-39]. Our studies demonstrate that expression
of PER 2 results in a significant decrease in the number
and size of colonies formed by MCF-7 cells in soft agar.
Together these data demonstrate that expression of PER 2
significantly inhibits anchorage-independent growth of
MCF-7 cells.
Finally, Western blot analysis demonstrates that PER 2 is
endogenously expressed in normal/transformed human
breast epithelial cell lines but is not expressed or expressed
at a significantly reduced level in human breast cancer cell
lines. The fact that expression of PER 2 alone inhibits
MCF-7 cell proliferation and induces apoptosis suggests
that reduced expression or altered function of PER 2 may
be a mechanism via which mammary epithelial cells
escape programmed cell death and progress to a malig-
nant phenotype.
Our studies, as well as those of Fu et al. [28] and Gery et
al. [32] clearly demonstrate the tumor suppressive nature
of PER 2 as evinced by inhibition of cell growth, induction
of apoptosis, reduced colony formation and growth in
soft agar. Furthermore, our studies shown that, although
PER 2 can function independently as a tumor suppressor,
its activity is significantly enhanced in the presence of its
normal clock partner CRY 2. Based on our data and on
results previously described in the literature, we feel con-
fident that the loss of PER 2 is associated with some forms
of breast cancer. However, we cannot say for certain if theJournal of Circadian Rhythms 2008, 6:4 http://www.jcircadianrhythms.com/content/6/1/4
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link between loss of PER 2 function and cancer develop-
ment is mediated by disruption of circadian rhythmicity.
Numerous studies have demonstrated that clock genes,
including Per 2, are expressed in peripheral tissues, and
that some are subservient to the master clock in the SCN.
Future studies will address the association and regulation
of the SCN clock by photoperiod and the feed down effect
of photoperiod onto clock function in peripheral cells
including the epithelium of t he breast.
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